CN116421775A - Lactoferrin gel dressing, preparation method and application - Google Patents
Lactoferrin gel dressing, preparation method and application Download PDFInfo
- Publication number
- CN116421775A CN116421775A CN202310438974.7A CN202310438974A CN116421775A CN 116421775 A CN116421775 A CN 116421775A CN 202310438974 A CN202310438974 A CN 202310438974A CN 116421775 A CN116421775 A CN 116421775A
- Authority
- CN
- China
- Prior art keywords
- lactoferrin
- chitosan
- graphene oxide
- dopamine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 75
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 74
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 74
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 74
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 86
- 229920001661 Chitosan Polymers 0.000 claims abstract description 70
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 53
- 239000000499 gel Substances 0.000 claims abstract description 47
- 229960003638 dopamine Drugs 0.000 claims abstract description 43
- 239000002121 nanofiber Substances 0.000 claims abstract description 43
- 239000000835 fiber Substances 0.000 claims abstract description 38
- 239000011159 matrix material Substances 0.000 claims abstract description 19
- 239000008273 gelatin Substances 0.000 claims abstract description 17
- 229920000159 gelatin Polymers 0.000 claims abstract description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 29
- 238000002156 mixing Methods 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 14
- 108010010803 Gelatin Proteins 0.000 claims description 12
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 12
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 12
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 12
- 235000019322 gelatine Nutrition 0.000 claims description 12
- 235000011852 gelatine desserts Nutrition 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 238000010008 shearing Methods 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- 239000005714 Chitosan hydrochloride Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000010041 electrostatic spinning Methods 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 229920003169 water-soluble polymer Polymers 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- -1 polytetrafluoroethylene Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 206010072170 Skin wound Diseases 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000007974 sodium acetate buffer Substances 0.000 claims description 3
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 3
- 230000007480 spreading Effects 0.000 claims description 3
- 238000003892 spreading Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 230000037314 wound repair Effects 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 abstract description 6
- 102000004169 proteins and genes Human genes 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000010668 complexation reaction Methods 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000017 hydrogel Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000009818 osteogenic differentiation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0038—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the technical field of biological composite materials, in particular to a lactoferrin gel dressing, a preparation method and application. The lactoferrin gel dressing provided by the invention has a three-dimensional cross-linked network structure, and comprises a bulk network structure formed by dopamine-coated graphene oxide fibers and chitosan nanofibers, lactoferrin which is diffused and attached on the bulk network, and a matrix which coats the bulk network. The preparation method has the beneficial effects that the dopamine-coated graphene oxide fiber and the chitosan nanofiber with the lactoferrin attached to the surface are added to form a skeleton, and the dopamine and the lactoferrin attached to the graphene oxide fiber and the chitosan nanofiber are slowly released along with degradation and absorption of the graphene oxide fiber and the chitosan nanofiber, so that the curative effect is stable and durable. The gel prepared by taking chitosan and glycerol-gelatin as gel matrixes is uniform and fine, does not carry out protein complexation with lactoferrin, and has the advantages of low cost, easy acquisition of matrixes, simple preparation process, controllable quality and high safety.
Description
Technical Field
The invention relates to the technical field of biological composite materials, in particular to a lactoferrin gel dressing, a preparation method and application.
Background
The hydrogel is a water-soluble hydrophilic polymer material, can form a three-dimensional network structure through physical or chemical crosslinking, and has the advantages of high water content, good biocompatibility and the like. The hydrogel dressing is used as an emerging functional wound dressing, can keep the wound moist and continuously absorb wound exudates compared with the traditional dressing, and partial hydrogel prepared from chitosan, polypeptides and the like can be timely degraded so as to avoid secondary damage caused by dressing replacement. More importantly, the hydrogel dressing can be endowed with various excellent performances through structural design and functional integration, and further plays an important role in various wound healing processes. Such as: the hydrogel with hemostatic function can firmly adhere to the wound, block hemostasis and promote coagulation. The antibacterial hydrogel can realize high-efficiency antibacterial performance by utilizing the antibacterial performance of the antibacterial hydrogel or loading nano antibacterial materials or antibiotics. Anti-inflammatory hydrogels can alleviate inflammatory responses by controlled loading and smart release of growth factors or anti-inflammatory drugs. The tissue regeneration promoting hydrogel can promote vascularization, granulation tissue regeneration and wound epithelialization through controllable loading and intelligent release of small molecule drugs, growth factors or cytokines. In addition, the anti-freezing heat-resistant hydrogel, the electronic skin and other advanced functional dressings can also be used as the dressing for accelerating wound healing under extreme conditions.
Lactoferrin (LF) is a natural active iron-binding glycoprotein with multiple physiological functions, mainly derived from milk of mammals, and is not only involved in the transportation of iron in organisms and promoting the growth and differentiation of bone cells, but also has the functions of resisting microorganisms, viruses, oxidation, cancers and the like. Among the many biological functions, its antibacterial activity is the most attractive. A large number of researches show that the lactoferrin has good inhibition capability to various gram-negative bacteria, gram-positive bacteria and some fungi, has no toxic or side effect to human bodies, is recognized as a safe food preservative auxiliary agent, and is widely applied to the field of foods.
In the prior art, the gel dressing using lactoferrin as one of the raw materials is often chemically crosslinked, so that protein denaturation is easy to occur in the reaction process, and in addition, the release rate of the gel on low-molecular drugs such as protein, polypeptide and the like is too fast. Therefore, a gel dressing which has good broad-spectrum antibacterial function, lasting drug effect and good slow release effect needs to be studied.
Disclosure of Invention
The invention aims to provide a lactoferrin gel dressing, a preparation method and application thereof, and the gel dressing has good physicochemical property, biodegradability and biocompatibility, and can release drugs to form continuous antibacterial activity after use.
The technical scheme for solving the technical problems is as follows:
a lactoferrin gel dressing has a three-dimensional cross-linked network structure, and comprises a bulk network structure formed by dopamine-coated graphene oxide fibers and chitosan nanofibers, lactoferrin which is diffused and attached on the bulk network, and a matrix which coats the bulk network.
As a preferred embodiment of the present invention, the matrix comprises chitosan, glycerol-gelatin.
The invention also discloses a preparation method of the lactoferrin gel dressing, which comprises the steps of preparing the dopamine-coated graphene oxide fiber, preparing the chitosan nanofiber and preparing a matrix:
the preparation of the dopamine-coated graphene oxide fiber comprises the following steps: mixing graphene oxide powder with deionized water, performing ultrasonic treatment, and centrifuging to obtain graphene oxide dispersion liquid;
adding an acetic acid-sodium acetate buffer solution and dopamine powder into the graphene oxide dispersion liquid, and stirring to obtain a mixed solution;
spreading the mixed solution on a polytetrafluoroethylene plate, drying, removing the film, curling and cutting into fibers;
the preparation of the chitosan nanofiber comprises the following steps:
mixing chitosan with diluted hydrochloric acid respectively, dissolving, and drying to obtain chitosan hydrochloride;
mixing and dissolving chitosan hydrochloride with water-soluble polymer, tris buffer solution and lactoferrin, and carrying out electrostatic spinning to obtain chitosan nanofiber with the lactoferrin attached to the surface;
the preparation method of the matrix comprises the following steps:
adding gelatin into water, soaking for 35min, adding glycerol, ethylparaben and the dopamine-coated graphene oxide fibers, then heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding chitosan and the chitosan nanofiber with lactoferrin attached to the surface, and stirring again and mixing uniformly to obtain the lactoferrin gel dressing.
As a preferable technical scheme of the invention, in the preparation process of the dopamine-coated graphene oxide fiber, the graphene oxide concentration of the graphene oxide dispersion liquid is regulated to be 1.5-3 mg/ml.
As a preferable technical scheme of the invention, in the preparation process of the chitosan nanofiber, the Tris buffer solution is prepared by mixing 0.1-0.2M Tris solution with hydrochloric acid according to a volume ratio of 1: mixing 0.8-1, constant volume and pH value of 7.0-7.2, steam sterilizing at 0.1-0.15 MPa for 30min, and refrigerating.
As a preferable technical scheme of the invention, the lactoferrin is uniformly diffused and adsorbed on the chitosan nanofiber under the action of electrostatic force in the electrostatic spinning process.
As a preferable technical scheme of the invention, in the preparation process of the matrix, the mass fraction of each component in the matrix is as follows: 1.2 to 1.4 weight percent of gelatin, 13 to 14 weight percent of glycerin, 0.03 to 0.035 weight percent of ethylparaben, 5.0 to 5.6 weight percent of dopamine-coated graphene oxide fiber, 0.92 to 0.94 weight percent of chitosan, 4.5 to 5.5 weight percent of chitosan nanofiber with lactoferrin attached to the surface, and the balance of water.
As a preferable technical scheme of the invention, the water-soluble polymer is polyethylene glycol or polyvinyl alcohol.
The invention also discloses application of the lactoferrin gel dressing prepared by the method in repairing skin wound surfaces.
The invention has the beneficial effects that:
the dopamine-coated graphene oxide fiber and the chitosan nanofiber with the lactoferrin attached to the surface are added into the gel dressing to form a skeleton, and the dopamine and the lactoferrin attached to the graphene oxide fiber and the chitosan nanofiber are slowly released along with degradation and absorption of the graphene oxide fiber and the chitosan nanofiber, so that the gel dressing has a stable and durable curative effect. The gel prepared by taking chitosan and glycerol-gelatin as gel matrixes is uniform and fine, does not carry out protein complexation with lactoferrin, and has the advantages of low cost, easy acquisition of matrixes, simple preparation process, controllable quality and high safety.
Drawings
FIG. 1 is a scanning electron micrograph of a lactoferrin gel dressing of the present invention;
FIG. 2 is a scanning electron micrograph of a dopamine encapsulated graphene oxide fiber of the present invention;
FIG. 3 is a scanning electron micrograph of a chitosan nanofiber with lactoferrin attached to the surface of the nanofiber.
The technical scheme of the invention is further described in detail through specific implementation modes and examples.
Detailed Description
The following detailed description of the present invention will provide a clear and complete description of the technical solution of the present invention, and it is apparent that the described embodiments are some, but not all, embodiments of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Bacterial infection is one of the most common problems in impeding wound healing or skin regeneration. In the repair process, inflammatory reaction caused by wound infection can obviously reduce the healing quality of the wound and prolong the healing time of the wound. In severe cases, wound healing may fail, leading to complications. To solve this problem, researchers often add antimicrobial materials to hydrogels to achieve antimicrobial effects. The most commonly used antibacterial agents in previous studies are antibiotics. However, long-term use of antibiotics can cause resistance, and cannot guarantee an optimal wound repair environment. It is important to develop a multifunctional strategy to treat bacterial infections while promoting wound healing.
The specific embodiment of the invention discloses a lactoferrin gel dressing, which is shown in figure 1 and has a three-dimensional cross-linked network structure, wherein the cross-linked network structure comprises a bulk network structure formed by dopamine-coated graphene oxide fibers and chitosan nanofibers, lactoferrin which is diffused and attached on the bulk network, and a matrix which wraps the bulk network. Wherein the matrix comprises chitosan, glycerol-gelatin.
As shown in fig. 3, the lactoferrin gel dressing of the present invention adopts dopamine-coated graphene oxide fiber as one of the raw materials, and Dopamine (DA) -coated graphene oxide having reducibility has antioxidant activity, conductivity, adhesiveness and rapid hemostatic effect. The Dopamine (DA) endows the gel with excellent antioxidant activity, conductivity, self-healing property and in-vivo antibacterial activity, and interaction between catechol and quinone groups on the Dopamine (DA) and Polydopamine (PDA) and amino and thiol groups on proteins further endows the hydrogel with good tissue adhesion, and good hemostatic performance is shown in experiments. Meanwhile, graphene is used to accelerate osteogenic differentiation of human bone marrow mesenchymal stem cells, and is also used to fabricate a biosensor of epitaxial graphene on silicon carbide. Meanwhile, the graphene can be used as a nerve interface electrode without changing or damaging performance, such as promoting scar tissue formation. Due to the characteristics of flexibility, biocompatibility, conductivity and the like, the graphene oxide is very effective in inhibiting the growth of escherichia coli, does not hurt human cells, and can promote the healing of wound surfaces while inhibiting bacteria.
And as a second raw material, as shown in fig. 2, the lactoferrin-chitosan nanofiber also has a very remarkable effect. Chitosan (Chitosan), also known as chitin, chitosan, chemical name polyglucosamine (1-4) -2-amino-beta-D glucose, is a deacetylation product of chitin, is derived from plant, fungal cell walls, arthropod exoskeleton and the like, is the only basic polysaccharide found in large quantities in nature so far, and is white powder or flaky solid. The antibacterial mechanism of chitosan is: the amino group with positive charge in chitosan has electrostatic action with protein or phospholipid with negative charge on the surface of bacteria, so that the surface structure of bacteria is destroyed; chitosan can penetrate through cell walls and cell membranes to enter the inside of bacteria, and can be combined with DNA to prevent the transcription of bacterial DNA; chitosan chelates with metal ions, preventing uptake of trace elements and binding with nutrients necessary for bacterial growth. Lactoferrin is capable of competitively depriving bacteria of the iron element required for growth by chelating iron ions, thereby inhibiting the growth of bacteria. Lactoferrin has also been shown to bind to lipid a, causing the release of lipid a from the bacterial wall of gram-negative bacteria, leading to bacterial death. Thus having broad-spectrum capability of resisting gram-positive bacteria, gram-negative bacteria and fungi and effectively inhibiting the growth of escherichia coli, salmonella typhi, streptococcus, legionella pneumophila and staphylococcus aureus. After oral treatment of lactoferrin is clinically administered to patients, infection of gastrointestinal bacteria is reduced, but growth of lactobacillus and bifidobacteria is not affected.
The specific embodiment of the invention provides a preparation method of the lactoferrin gel dressing, which comprises the steps of preparing dopamine-coated graphene oxide fibers, preparing chitosan nanofibers and preparing a matrix:
the preparation of the dopamine-coated graphene oxide fiber comprises the following steps: mixing graphene oxide powder with deionized water, performing ultrasonic treatment, and centrifuging to obtain graphene oxide dispersion liquid;
adding an acetic acid-sodium acetate buffer solution and dopamine powder into the graphene oxide dispersion liquid, and stirring to obtain a mixed solution;
and (3) spreading the mixed solution on a polytetrafluoroethylene plate, drying, removing the film, curling and cutting into fibers.
The preparation of the chitosan nanofiber comprises the following steps:
mixing chitosan with diluted hydrochloric acid respectively, dissolving, and drying to obtain chitosan hydrochloride;
mixing and dissolving chitosan hydrochloride with water-soluble polymer, tris buffer solution and lactoferrin, and carrying out electrostatic spinning to obtain the chitosan nanofiber with the lactoferrin attached to the surface.
The preparation method of the matrix comprises the following steps:
adding gelatin into water, soaking for 35min, adding glycerol, ethylparaben and the dopamine-coated graphene oxide fibers, then heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding chitosan and the chitosan nanofiber with lactoferrin attached to the surface, and stirring again and mixing uniformly to obtain the lactoferrin gel dressing.
Further, in the preparation process of the dopamine-coated graphene oxide fiber, the graphene oxide concentration of the graphene oxide dispersion liquid is regulated to be 1.5-3 mg/ml.
Further, in the preparation process of the chitosan nanofiber, the Tris buffer solution is prepared by mixing 0.1-0.2M Tris solution with hydrochloric acid according to a volume ratio of 1: mixing 0.8-1, constant volume and pH value of 7.0-7.2, steam sterilizing at 0.1-0.15 MPa for 30min, and refrigerating.
Furthermore, the lactoferrin is uniformly diffused and adsorbed on the chitosan nanofiber under the action of electrostatic force in the electrostatic spinning process.
Further, in the preparation process of the matrix, the mass fraction of each component in the matrix is as follows: 1.2 to 1.4 weight percent of gelatin, 13 to 14 weight percent of glycerin, 0.03 to 0.035 weight percent of ethylparaben, 5.0 to 5.6 weight percent of dopamine-coated graphene oxide fiber, 0.92 to 0.94 weight percent of chitosan, 4.5 to 5.5 weight percent of chitosan nanofiber with lactoferrin attached to the surface, and the balance of water.
In addition, the specific embodiment of the invention also provides an application mode of the lactoferrin gel dressing, and the lactoferrin gel dressing can be applied to repairing skin wound surfaces.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Adding 1.2g of gelatin into 60g of water, soaking for 35min, adding 12.5g of glycerin, 0.03g of ethylparaben and 3.5g of dopamine-coated graphene oxide fibers, then heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding 3g of chitosan and 3g of chitosan nanofiber with lactoferrin attached to the surface, and stirring and mixing again to obtain the lactoferrin gel dressing.
Example 2
Adding 1.5g of gelatin into 60g of water, soaking for 35min, adding 14g of glycerin, 0.05g of ethylparaben and 4.2g of dopamine-coated graphene oxide fibers, heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding 4g of chitosan and 3g of chitosan nanofiber with lactoferrin attached to the surface, and stirring and mixing again to obtain the lactoferrin gel dressing.
Example 3
Adding 1.3g of gelatin into 60g of water, soaking for 35min, adding 13g of glycerin, 0.04g of ethylparaben and 3.8g of dopamine-coated graphene oxide fibers, heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding 4g of chitosan and 4g of chitosan nanofiber with lactoferrin attached to the surface, and stirring and mixing again to obtain the lactoferrin gel dressing.
Comparative example 1
Adding 1.2g of gelatin into 60g of water, soaking for 35min, adding 12.5g of glycerin, 0.03g of ethylparaben and 8g of dopamine-coated graphene oxide fibers, heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding 4g of chitosan, stirring again and mixing uniformly to obtain the lactoferrin-free gel dressing.
Comparative example 2
Adding 1.5g of gelatin into 60g of water, soaking for 35min, adding 14g of glycerol and 0.05g of ethylparaben, heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding 4g of chitosan and 8g of chitosan nanofiber with lactoferrin attached to the surface, and stirring and mixing again to obtain the dopamine-free coated lactoferrin gel dressing.
In order to verify the beneficial effects of the examples of the present invention, the microbial inhibition experiments were performed on the above examples and comparative examples:
1. aerobic and mould experiments
1.0g of each of the gel dressings of examples and comparative examples was mixed with 100ml of sodium chloride peptone buffer pH7.0, and dissolved as a test solution. After membrane filtration, the membrane was rinsed with 100mL of sodium chloride peptone buffer pH7.0, and after filtration, the membrane was attached with the bacterial side facing upwards to the medium. Culturing the aerobic bacteria at 35 ℃ for 3d; the mould is cultivated at 25 ℃ for 5 days. Two replicates were made for each group.
2. Experiment of Staphylococcus aureus
1.0g of each of the gel dressings of examples and comparative examples was mixed with 100ml of sodium chloride peptone buffer pH7.0, and dissolved as a test solution. After membrane filtration, the membrane was rinsed with 100mL of pH7.0 sodium chloride peptone buffer solution, and after filtration, the membrane was added to 15mL of trypticase soyase liquid medium and incubated at 35℃for 20 hours. The culture was inoculated onto sodium chloride agar medium and cultured at 35℃for 1d.
3. Candida albicans experiment
1.0g of the sample was added to 100mL of sodium chloride peptone buffer pH7.0, and the mixture was stirred and dissolved to prepare a sample solution. After membrane filtration, the membrane was rinsed with 100mL of pH7.0 sodium chloride peptone buffer solution, and after filtration, the membrane was added to 15mL of glucose-containing liquid medium and incubated at 35℃for 4d. The culture was streaked on a plate of glucose agar medium and cultured at 35℃for 36 hours.
The experimental results are as follows:
from the above table, since the comparative examples adopt the amounts of the dopamine-coated graphene oxide fibers of the super examples 1 to 3 and the chitosan nanofibers with lactoferrin attached to the surfaces, and the experimental results are combined, it can be proved that the lactoferrin-chitosan nanofibers and the dopamine-coated graphene oxide fibers of the embodiment of the present invention can play a synergistic role, and compared with the comparative examples containing only one of them, the antibacterial effect is significantly better, rather than the antibacterial effect generated by the additive effect of the dopamine-coated graphene oxide fibers and the chitosan nanofibers with lactoferrin attached to the surfaces.
Further, in order to demonstrate the slow release effect of the gel dressing of the present invention, comparative example 3 was additionally provided, specifically as follows:
comparative example 3
Adding 1.5g of gelatin into 60g of water, soaking for 35min, adding 14g of glycerol and 0.05g of ethylparaben, heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding 6g of chitosan and 6g of lactoferrin powder, and stirring and mixing again to obtain the dopamine-coated graphene oxide fiber-lactoferrin gel dressing without the chitosan nanofiber with lactoferrin attached to the surface.
OD value measurements were performed in candida albicans experiments on the above examples 1 to 3 and comparative examples 1 to 3, and the results were as follows:
therefore, the antibacterial effect of the embodiment 1-3 of the invention can be strongest within 6 to 9 hours, the antibacterial effect is still stronger within 9 to 12 hours, the antibacterial effect of the comparative example starts to be weakened after 3 hours, and compared with the antibacterial capability of the embodiment of the invention, the difference is larger, so that the dopamine-coated graphene oxide fiber and the chitosan nanofiber with the lactoferrin attached to the surface can play a better role in slow-release antibacterial effect in the slow degradation process.
While the preferred embodiment of the present invention has been illustrated and described, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms and equivalents thereof without departing from the spirit of the invention.
Claims (9)
1. A lactoferrin gel dressing, characterized by having a three-dimensional cross-linked network structure, comprising a bulk network structure formed by dopamine-coated graphene oxide fibers and chitosan nanofibers, lactoferrin diffusion attached to the bulk network, and a matrix coating the bulk network.
2. The lactoferrin gel dressing of claim 1, wherein the matrix comprises chitosan, glycerol-gelatin.
3. A method for preparing the lactoferrin gel dressing as claimed in claim 1 or 2, characterized by comprising the preparation of dopamine-coated graphene oxide fibers, the preparation of chitosan nanofibers and the preparation of a matrix:
the preparation of the dopamine-coated graphene oxide fiber comprises the following steps: mixing graphene oxide powder with deionized water, performing ultrasonic treatment, and centrifuging to obtain graphene oxide dispersion liquid;
adding an acetic acid-sodium acetate buffer solution and dopamine powder into the graphene oxide dispersion liquid, and stirring to obtain a mixed solution;
spreading the mixed solution on a polytetrafluoroethylene plate, drying, removing the film, curling and cutting into fibers;
the preparation of the chitosan nanofiber comprises the following steps:
mixing chitosan with diluted hydrochloric acid respectively, dissolving, and drying to obtain chitosan hydrochloride;
mixing and dissolving chitosan hydrochloride with water-soluble polymer, tris buffer solution and lactoferrin, and carrying out electrostatic spinning to obtain chitosan nanofiber with the lactoferrin attached to the surface;
the preparation method of the matrix comprises the following steps:
adding gelatin into water, soaking for 35min, adding glycerol, ethylparaben and the dopamine-coated graphene oxide fibers, then heating to 60-70 ℃ for high-speed shearing and stirring, cooling to below 30 ℃, adding chitosan and the chitosan nanofiber with lactoferrin attached to the surface, and stirring again and mixing uniformly to obtain the lactoferrin gel dressing.
4. The method for preparing a lactoferrin gel dressing as claimed in claim 3, wherein, in the preparation process of the dopamine-coated graphene oxide fiber, the graphene oxide concentration of the graphene oxide dispersion liquid is regulated to be 1.5-3 mg/ml.
5. The method for preparing a lactoferrin gel dressing as claimed in claim 3, characterized in that, in the preparation process of the chitosan nanofiber, the Tris buffer solution is prepared by mixing 0.1-0.2M Tris solution with hydrochloric acid according to a volume ratio of 1: mixing 0.8-1, constant volume and pH value of 7.0-7.2, steam sterilizing at 0.1-0.15 MPa for 30min, and refrigerating.
6. A method of preparing a lactoferrin gel dressing as claimed in claim 3, wherein the lactoferrin is uniformly diffused and adsorbed on the chitosan nanofibers under the action of electrostatic force during the electrostatic spinning process.
7. A method of preparing a lactoferrin gel dressing as claimed in claim 3, wherein, in the preparation of the matrix, the mass fractions of the components in the matrix are: 1.2 to 1.4 weight percent of gelatin, 13 to 14 weight percent of glycerin, 0.03 to 0.035 weight percent of ethylparaben, 5.0 to 5.6 weight percent of dopamine-coated graphene oxide fiber, 0.92 to 0.94 weight percent of chitosan, 4.5 to 5.5 weight percent of chitosan nanofiber with lactoferrin attached to the surface, and the balance of water.
8. A method of preparing a lactoferrin gel dressing as claimed in claim 3, in which the water soluble polymer is polyethylene glycol or polyvinyl alcohol.
9. Use of a lactoferrin gel dressing as defined in claim 1 or 2 or a lactoferrin gel dressing as prepared by the method of any one of claims 3 to 8 for skin wound repair.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310438974.7A CN116421775A (en) | 2023-04-21 | 2023-04-21 | Lactoferrin gel dressing, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310438974.7A CN116421775A (en) | 2023-04-21 | 2023-04-21 | Lactoferrin gel dressing, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116421775A true CN116421775A (en) | 2023-07-14 |
Family
ID=87092524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310438974.7A Pending CN116421775A (en) | 2023-04-21 | 2023-04-21 | Lactoferrin gel dressing, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421775A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040142037A1 (en) * | 2002-09-16 | 2004-07-22 | Jose Engelmayer | Lactoferrin compositions and methods of wound treatment |
| CN106084257A (en) * | 2016-06-06 | 2016-11-09 | 东华大学 | A kind of composite aquogel and preparation method thereof |
| CN107496971A (en) * | 2017-07-27 | 2017-12-22 | 东华大学 | A kind of bacteria cellulose/lactoferrin antiseptic dressing and preparation method thereof |
| CN110694594A (en) * | 2018-06-25 | 2020-01-17 | 香港城市大学深圳研究院 | Preparation method of porous material based on graphene oxide, chitosan and dopamine |
| CN112587708A (en) * | 2021-01-04 | 2021-04-02 | 潘伟 | Collagen peptide wound dressing and preparation method thereof |
| CN115869453A (en) * | 2021-09-26 | 2023-03-31 | 中国科学院理化技术研究所 | Double-layer antibacterial dressing loaded with antibacterial molecules, preparation and application |
-
2023
- 2023-04-21 CN CN202310438974.7A patent/CN116421775A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040142037A1 (en) * | 2002-09-16 | 2004-07-22 | Jose Engelmayer | Lactoferrin compositions and methods of wound treatment |
| CN106084257A (en) * | 2016-06-06 | 2016-11-09 | 东华大学 | A kind of composite aquogel and preparation method thereof |
| CN107496971A (en) * | 2017-07-27 | 2017-12-22 | 东华大学 | A kind of bacteria cellulose/lactoferrin antiseptic dressing and preparation method thereof |
| CN110694594A (en) * | 2018-06-25 | 2020-01-17 | 香港城市大学深圳研究院 | Preparation method of porous material based on graphene oxide, chitosan and dopamine |
| CN112587708A (en) * | 2021-01-04 | 2021-04-02 | 潘伟 | Collagen peptide wound dressing and preparation method thereof |
| CN115869453A (en) * | 2021-09-26 | 2023-03-31 | 中国科学院理化技术研究所 | Double-layer antibacterial dressing loaded with antibacterial molecules, preparation and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110354295B (en) | Photo-thermal conversion material and preparation method thereof | |
| CN112480434B (en) | Copper ion antibacterial hydrogel and preparation method and application thereof | |
| CN110448721B (en) | Antibacterial adhesive conductive hemostatic and antioxidant injectable composite hydrogel and preparation method and application thereof | |
| CN105288704B (en) | A kind of polyamide-amide dendrimer modification of chitosan wound repair hydrogel and its preparation method and application | |
| CN112851951B (en) | Dialdehyde chitosan grafted with epsilon-polylysine and preparation method and application thereof | |
| CN114984300B (en) | Tough antibacterial hydrogel dressing and preparation method thereof | |
| CN110152055B (en) | Functional drug sustained-release medical dressing constructed by alginic acid aminated derivative/bacterial cellulose nanocrystalline composite gel | |
| CN112451738B (en) | Silver ion polysaccharide polymer antibacterial dressing and preparation method and application thereof | |
| CN109851844A (en) | A kind of preparation method and application of the modified antimicrobial calcium alginate sponge of situ-formed graft | |
| CN113069591A (en) | Chitosan-calcium polyglutamate biological dressing and preparation method thereof | |
| WO2013028214A1 (en) | Antimicrobial hydrogel wound dressing | |
| CN115850733B (en) | Nanoclay hydrogel for injection and preparation method and application thereof | |
| CN116421775A (en) | Lactoferrin gel dressing, preparation method and application | |
| CN111234163B (en) | Nanogel with antibacterial repair performance and preparation method and application thereof | |
| CN114456239A (en) | Shengtai element, external antibacterial peptide gel preparation prepared from Shengtai element and application of gel preparation | |
| CN112791100A (en) | Composite antibacterial microsphere with efficient active oxygen scavenging function and preparation method thereof | |
| CN109384943B (en) | Preparation method of antibacterial high-strength chitosan/heparin sodium ion compound self-assembled hydrogel membrane | |
| CN112870431A (en) | Antibacterial hydrogel with G-quadruplex structure and used as cascade reactor, and preparation method and application thereof | |
| US20230381325A1 (en) | Long-lasting hydrogel for use against drug-resistant bacteria and preparation method and use thereof | |
| CN116236609B (en) | Antibacterial and anti-inflammatory bandage and preparation method and application thereof | |
| CN116082694B (en) | Sponge compound for tissue wound repair and preparation method thereof | |
| CN114796592B (en) | Preparation method of chitosan-based antibacterial gel | |
| Seeyangnok et al. | Encapsulation of Turmeric Crude Extracted in Chitosan Hydrogel Beads for Antimicrobial in Animal Health Care Applications | |
| CN115624647B (en) | Biological film medical dressing compounded with wound healing medicine and film essence, and preparation method and application thereof | |
| CN112048083B (en) | Preparation method of guanidino-containing antibacterial polymer for promoting diabetic ulcer skin repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |